Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix and Semaglutide in Recent-Onset Type 1 Diabetes
NCT07614412Phase 2Not yet recruiting
- Sponsor
- Ministry of Health
- Start
- Jan 2027
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Zoster vaccine recombinant and semaglutide in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Ministry of Health. Primary endpoint: 2-hour stimulated C-peptide Area Under the Curve at 12 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
Zoster vaccine recombinantsemaglutide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07614412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614412.